Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Leukemia, Myeloid, Chronic-Phase 22Leukemia 21Gastrointestinal Stromal Tumors 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasms 8Blast Crisis 7Neoplasm Metastasis 6Philadelphia Chromosome 4Myeloproliferative Disorders 4Melanoma 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Colorectal Neoplasms 2Substance Withdrawal Syndrome 1Sarcoma 1Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Peritoneal Neoplasms 1Neurofibromatoses 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease Progression × nilotinib × Clear all
NCT01110668 2017-02-28

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Novartis

Phase 2 Completed
2 enrolled
GastrointestinalSarcoma

Disease Progression, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡